GlassScriptPhysician profile
Gerrit J Schipper
NPI 1134101884
$17,191.36
in general payments reported to CMS, 2019-2025
42 companies · $539 in 2025
The $539 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,923 · 2020: $729 · 2021: $7,200 · 2022: $407 · 2023: $5,546 · 2024: $848 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,683 · Food and Beverage: $2,147 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,683.40 |
| Food and Beverage | $2,146.96 |
| Education | $102.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $8,972.45 | 2021-2025 | Nexplanon |
| Renovia INC | $1,996.10 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $1,477.16 | 2020-2025 | Gardasil 9 |
| Abbvie INC. | $719.74 | 2019-2025 | Orilissa, Lo Loestrin Fe |
| Coloplast Corp | $579.11 | 2019-2023 | Altis |
| Astellas Pharma US INC | $573.79 | 2019-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $420.27 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $314.00 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $251.35 | 2023-2025 | Gemtesa, Myfembree |
| Daiichi Sankyo INC. | $228.86 | 2022-2024 | Injectafer |
| Therapeuticsmd, INC. | $228.14 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $168.80 | 2019 | |
| Aspira Women'S Health INC | $125.20 | 2021-2024 | Ova1 |
| Amgen INC. | $123.43 | 2023-2025 | Evenity, Prolia, Prolia |
| Ethicon US, LLC | $119.10 | 2023-2025 | Enseal, Vistaseal, Stratafix |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caldera Medical, INC | $85.09 | 2021 | |
| Coopersurgical, INC. | $83.47 | 2021-2024 | Paragard T 380a, Summit Doppler, Paragard T 380a |
| Hologic Sales and Service, LLC | $77.21 | 2021-2024 | Aptima, Thinprep 2000 Processor |
| Allergan, INC. | $75.59 | 2019-2020 | |
| Millicent US INC | $66.99 | 2020-2024 | Intrarosa, Femring |
| Axonics, INC. | $66.94 | 2023 | Axonics |
| Kci USA, INC. | $43.73 | 2019-2023 | Prevena, V.A.C.Ulta, V.A.C. Veraflo |
| Acella Pharmaceuticals, LLC | $42.08 | 2024-2025 | NP Thyroid 60 |
| Sage Therapeutics, LLC | $38.68 | 2025 | Zurzuvae |
| Alexion Pharmaceuticals, INC. | $32.07 | 2019 | |
| Smith+Nephew, INC. | $29.27 | 2020-2023 | Pico |
| Evofem Biosciences, INC. | $27.83 | 2020-2021 | |
| Shield Therapeutics INC | $26.21 | 2024 | |
| Minerva Surgical, INC | $25.06 | 2024 | |
| Optumhealth Care Solutions, LLC | $24.06 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
| Lumenis, INC | $19.38 | 2021 | |
| Exeltis, USA INC. | $18.14 | 2024 | Slynd |
| Cumberland Pharmaceuticals, INC. | $18.06 | 2023 | Kristalose |
| Vertex Pharmaceuticals Incorporated | $17.21 | 2025 | |
| Mylan Pharmaceuticals INC. | $16.90 | 2021 | |
| Medtronic, INC. | $16.58 | 2022 | |
| Boston Scientific Corporation | $15.67 | 2019 | |
| Agile Therapeutics, INC. | $13.97 | 2021 | |
| Seqirus USA INC | $13.67 | 2025 | Fluad, Flucelvax |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerrit Schipper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.